Drug Trial Radar · NCT06677060
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
11,300
Planned (sponsor's estimate)
Start
Mar 14, 2025
Primary completion
Dec 17, 2029
Study completion Dec 17, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent is required for the optional pre-screening period. The pre-screening assessments do not replace the full screening tests at Visit 1. Upon entering the screening period, all consented participants (after signature of screening ICF) will be screened during an up to 14-day screening period. Participants who meet all screening inclusion/exclusion criteria but are not treated with SGLT2i or are treated for less than 4 weeks will enter a run-in period with dapagliflozin 10 mg once daily for at least 4 weeks (and not more than 6 weeks) before randomisation. Site visits will take place at approximately 2-, 4-, 8-, 16-, and 34-weeks following randomisation. Thereafter visits will occur approximately every 4 months. The study closure procedures will be initiated when the predetermined number of the first secondary endpoint events (ie, the composite of hospitalisation for HF or CV death) is predicted to have occurred i.e., the PACD. In case of premature discontinuation of the blinded study intervention, participants will remain in the study. Unless a participant meets the dapagliflozin specific discontinuation criteria, they will continue to receive open label dapagliflozin 10 mg. It is important that the scheduled study visits and data collection continue according to the study protocol.
Conditions
- Heart Failure
Interventions
Baxdrostat and dapagliflozinDrug
baxdrostat tablet and dapagliflozin tablet
Placebo and dapagliflozinOther
placebo tablet and dapagliflozin tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine if baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of an HF event or CV deathTime frame: Event driven; Up to 38 months
Locations
977 sites in 35 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Recruiting
Research Site
Centreville, Alabama · Recruiting
Research Site
Fairhope, Alabama · Recruiting
Research Site
Huntsville, Alabama · Recruiting
Research Site
Mobile, Alabama · Recruiting
Research Site
Sheffield, Alabama · Recruiting
Research Site
Vestavia Hills, Alabama · Recruiting
Research Site
Anchorage, Alaska · Withdrawn
Research Site
Gilbert, Arizona · Recruiting
Research Site
Glendale, Arizona · Completed
Research Site
Tempe, Arizona · Recruiting
Research Site
Tempe, Arizona · Not yet recruiting
Research Site
Tucson, Arizona · Recruiting
Research Site
Concord, California · Not yet recruiting
Research Site
Daly City, California · Not yet recruiting
Research Site
Dublin, California · Withdrawn
Research Site
Huntington Beach, California · Recruiting
Research Site
Inglewood, California · Recruiting
Research Site
La Jolla, California · Recruiting
Research Site
Lakewood, California · Withdrawn
Research Site
Lincoln, California · Recruiting
Research Site
Loma Linda, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Sacramento, California · Recruiting
Research Site
San Diego, California · Recruiting
Research Site
San Dimas, California · Recruiting
Research Site
San Francisco, California · Recruiting
Research Site
San Francisco, California · Withdrawn
Research Site
Santa Maria, California · Recruiting
Research Site
Sherman Oaks, California · Suspended
Research Site
Thousand Oaks, California · Recruiting
Research Site
Aurora, Colorado · Recruiting
Research Site
Englewood, Colorado · Recruiting
Research Site
Bridgeport, Connecticut · Recruiting
Research Site
Stamford, Connecticut · Recruiting
Research Site
Waterbury, Connecticut · Recruiting
Research Site
Boca Raton, Florida · Not yet recruiting
Research Site
Crystal River, Florida · Recruiting
Research Site
Fort Lauderdale, Florida · Withdrawn
Showing 40 of 977 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.